Actionability and Familial Uptake Following Opportunistic Genomic Screening in a Pediatric Cancer Cohort

Abstract

Abstract The care for patients with serious conditions is increasingly guided by genomic medicine, and genomic medicine may equally transform care for healthy individual if genomic population screening is implemented. This study examines the medical impact of opportunistic genomic screening (OGS) in a cohort of patients undergoing comprehensive genomic germline DNA testing for childhood cancer, including the impact on their relatives. Medical actionability and uptake after cascade testing in the period following disclosure of OGS results was quantified. A secondary finding was reported to 19/595 (3,2%) probands primarily in genes related to cardiovascular and lipid disorders. After a mean follow up time of 1.6 years (IQR: 0.57-1.92 yrs) only 12 (63%) of these variants were found to be medically actionable. Thirty-eight relatives underwent additional genetic or clinical testing due to the return of the secondary finding. Clinical follow up or treatment was planned in 16 relatives, and as in the probands, the prescribed treatment was primarily betablockers or cholesterol lowering therapy. No invasive procedures or implantation of medical devices were performed in probands or relatives, and no reproductive counseling was requested. After an average of 1.6 years of follow-up 2.25 relatives per family with an actionable finding had been tested. This real-world experience of OGS grants new insight into the potentials, pitfalls and derived health care demands of genotype-first screening. If OGS is undertaken, the resulting health care effect and impact on demand for genetic counseling and workup in relatives extends beyond the effect in the probands.